Sodium channel-inhibiting drugs and survival of breast, colon and prostate cancer: A population-based study

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Fairhurst, Caroline ^a   Watt, Ian ^a,b   Martin, Fabiola ^a,b   Bland, Martin ^a   Brackenbury, William J ^a  

^a UNIVERSITY OF YORK   (United Kingdom)

^b UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

VOLTAGE GATED SODIUM CHANNEL; VOLTAGE GATED SODIUM CHANNEL BLOCKING AGENT;

ADULT; AGED; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HEALTH SURVEY; HUMAN; KAPLAN MEIER METHOD; MALE; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COLONIC NEOPLASMS; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; PROGNOSIS; PROSTATIC NEOPLASMS; RISK FACTORS; VOLTAGE-GATED SODIUM CHANNEL BLOCKERS; VOLTAGE-GATED SODIUM CHANNELS;

EID: 84947736235     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16758     Document Type: Article

References (54)

1. Gupta, G. P. & Massague, J. Cancer metastasis: building a framework. Cell 127, 679-695, doi: 10.1016/j.cell.2006.11.001 (2006).
2. Brackenbury, W. J. & Isom, L. L. Na Channel beta Subunits: Overachievers of the Ion Channel Family. Front. Pharmacol. 2, 53, doi: 10.3389/fphar.2011.00053 (2011).
3. Brackenbury, W. J., Djamgoz, M. B. & Isom, L. L. An emerging role for voltage-gated Na+ channels in cellular migration: regulation of central nervous system development and potentiation of invasive cancers. Neuroscientist 14, 571-583, doi: 10.1177/1073858408320293 (2008).
4. Brackenbury, W. J. & Isom, L. L. Voltage-gated Na+ channels: potential for beta subunits as therapeutic targets. Expert Opin. Ther. Targets 12, 1191-1203, doi: 10.1517/14728222.12.9.1191 (2008).
5. Catterall, W. A. From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 26, 13-25 (2000).
6. + channel Nav 1.6 and β1 subunits in the coordinated regulation of excitability and neurite outgrowth. Proc. Natl. Acad. Sci. USA 107, 2283-2288, doi: 10.1073/pnas.0909434107 (2010).
7. + channel β1 subunit-mediated neurite outgrowth requires fyn kinase and contributes to central nervous system development in vivo. J. Neurosci. 28, 3246-3256, doi: 10.1523/JNEUROSCI.5446-07.2008 (2008).
8. Brackenbury, W. J., Yuan, Y., O'Malley, H. A., Parent, J. M. & Isom, L. L. Abnormal neuronal patterning occurs during early postnatal brain development of Scn1b-null mice and precedes hyperexcitability. Proc. Natl. Acad. Sci. USA 110, 1089-1094, doi: 10.1073/pnas.1208767110 (2013).
9. Mantegazza, M., Curia, G., Biagini, G., Ragsdale, D. S. & Avoli, M. Voltage-gated sodium channels as therapeutic targets in epilepsy and other neurological disorders. Lancet Neurol. 9, 413-424, doi: 10.1016/S1474-4422(10)70059-4 (2010).
10. George, A. L., Jr. Inherited disorders of voltage-gated sodium channels. J. Clin. Invest. 115, 1990-1999 (2005).
11. Black, J. A. & Waxman, S. G. Noncanonical roles of voltage-gated sodium channels. Neuron 80, 280-291, doi: 10.1016/j.neuron.2013.09.012 (2013).
12. Brackenbury, W. J. Voltage-gated sodium channels and metastatic disease. Channels (Austin) 6, 352-361, doi: 10.4161/chan.21910 (2012).
13. Driffort, V. et al. Ranolazine inhibits NaV1.5-mediated breast cancer cell invasiveness and lung colonization. Mol. Cancer 13, 264, doi: 10.1186/1476-4598-13-264 (2014).
14. Nelson, M., Yang, M., Dowle, A. A., Thomas, J. R. & Brackenbury, W. J. The sodium channel-blocking antiepileptic drug phenytoin inhibits breast tumour growth and metastasis. Mol. Cancer 14, 13, doi: 10.1186/s12943-014-0277-x (2015).
15. + channel expression to cell behaviors involved in the metastatic cascade in rat prostate cancer: I. lateral motility. J. Cell. Physiol. 195, 479-487 (2003).
16. Yang, M. et al. Therapeutic potential for phenytoin: targeting Na(v)1.5 sodium channels to reduce migration and invasion in metastatic breast cancer. Breast Cancer Res. Treat. 134, 603-615, doi: 10.1007/s10549-012-2102-9 (2012).
17. Abdul, M. & Hoosein, N. Inhibition by anticonvulsants of prostate-specific antigen and interleukin-6 secretion by human prostate cancer cells. Anticancer Res. 21, 2045-2048 (2001).
18. Fraser, S. P. et al. Voltage-gated sodium channel expression and potentiation of human breast cancer metastasis. Clin. Cancer. Res. 11, 5381-5389, doi: 10.1158/1078-0432.CCR-05-0327 (2005).
19. Tassara, M. et al. Valproic acid in combination with all-trans retinoic acid and intensive therapy for acute myeloid leukemia in older patients. Blood 123, 4027-4036, doi: 10.1182/blood-2013-12-546283 (2014).
20. Gottlicher, M. et al. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20, 6969-6978, doi: 10.1093/emboj/20.24.6969 (2001).
21. Wheler, J. J. et al. Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers. Cancer Chemother. Pharmacol. 73, 495-501, doi: 10.1007/s00280-014-2384-1 (2014).
22. + channel SCN5A is a key regulator of a gene transcriptional network that controls colon cancer invasion. Cancer Res. 70, 6957-6967, doi: 10.1158/0008-5472.CAN-10-1169 (2010).
23. Brackenbury, W. J., Chioni, A. M., Diss, J. K. & Djamgoz, M. B. The neonatal splice variant of Nav1.5 potentiates in vitro metastatic behaviour of MDA-MB-231 human breast cancer cells. Breast Cancer Res. Treat. 101, 149-160, doi: 10.1007/s10549-006-9281-1 (2007).
24. + channel expression in Mat-LyLu rat prostate cancer cell line. J. Physiol. 573, 343-356, doi: 10.1113/jphysiol.2006.106906 (2006).
25. + channel activity and Transwell migration in Mat-LyLu rat prostate cancer cell line. J. Cell. Physiol. 210, 602-608, doi: 10.1002/jcp.20846 (2007).
26. Nelson, M., Millican-Slater, R., Forrest, L. C. & Brackenbury, W. J. The sodium channel beta1 subunit mediates outgrowth of neurite-like processes on breast cancer cells and promotes tumour growth and metastasis. Int. J. Cancer 135, 2338-2351, doi: 10.1002/ijc.28890 (2014).
27. Besson, P. et al. How do voltage-gated sodium channels enhance migration and invasiveness in cancer cells? Biochim. Biophys. Acta 1848, 2493-2501, doi: 10.1016/j.bbamem.2015.04.013 (2015).
28. Chioni, A. M., Brackenbury, W. J., Calhoun, J. D., Isom, L. L. & Djamgoz, M. B. A novel adhesion molecule in human breast cancer cells: voltage-gated Na+ channel beta1 subunit. Int. J. Biochem. Cell Biol. 41, 1216-1227, doi: 10.1016/j.biocel.2008.11.001 (2009).
29. + channel activity. J. Cell. Physiol. 215, 77-81, doi: 10.1002/jcp.21289 (2008).
30. Gaitatzis, A. & Sander, J. W. The long-term safety of antiepileptic drugs. CNS Drugs 27, 435-455, doi: 10.1007/s40263-013-0063-0 (2013).
31. Campbell, T. J. & Williams, K. M. Therapeutic drug monitoring: antiarrhythmic drugs. Br. J. Clin. Pharmacol. 46, 307-319, doi: 10.1046/j.1365-2125.1998.t01-1-00768.x (1998).
32. Yildirim, S., Altun, S., Gumushan, H., Patel, A. & Djamgoz, M. B. Voltage-gated sodium channel activity promotes prostate cancer metastasis in vivo. Cancer Lett. 323, 58-61, doi: 10.1016/j.canlet.2012.03.036 (2012).
33. Vecht, C. J., Wagner, G. L. & Wilms, E. B. Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurol. 2, 404-409 (2003).
34. Lo, W. L., Donermeyer, D. L. & Allen, P. M. A voltage-gated sodium channel is essential for the positive selection of CD4(+) T cells. Nat. Immunol. 13, 880-887, doi: 10.1038/ni.2379 (2012).
35. Munster, P. et al. Clinical and biological effects of valproic acid as a histone deacetylase inhibitor on tumor and surrogate tissues: phase I/II trial of valproic acid and epirubicin/FEC. Clin. Cancer. Res. 15, 2488-2496, doi: 10.1158/1078-0432.ccr-08-1930 (2009).
36. Munster, P. et al. Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. J. Clin. Oncol. 25, 1979-1985, doi: 10.1200/jco.2006.08.6165 (2007).
37. Michaelis, M., Doerr, H. W. & Cinatl, J., Jr. Valproic acid as anti-cancer drug. Curr. Pharm. Des. 13, 3378-3393 (2007).
38. Singh, G., Driever, P. H. & Sander, J. W. Cancer risk in people with epilepsy: the role of antiepileptic drugs. Brain 128, 7-17, doi: 10.1093/brain/awh363 (2005).
39. IARC. Phenytoin. IARC Monogr. Eval. Carcinog. Risks Hum. 66, 175-237 (1996).
40. Singh, G., Bell, G. S., Driever, P. H. & Sander, J. W. Cancer risk in people with epilepsy using valproate-sodium. Acta Neurol. Scand. 125, 234-240, doi: 10.1111/j.1600-0404.2011.01607.x (2012).
41. Kang, H. et al. Long-term use of valproic acid in US veterans is associated with a reduced risk of smoking-related cases of head and neck cancer. Cancer 120, 1394-1400, doi: 10.1002/cncr.28479 (2014).
42. Neligan, A. et al. The long-term risk of premature mortality in people with epilepsy. Brain 134, 388-395, doi: 10.1093/brain/awq378 (2011).
43. Shackleton, D. P., Westendorp, R. G., Trenite, D. G. & Vandenbroucke, J. P. Mortality in patients with epilepsy: 40 years of follow up in a Dutch cohort study. J. Neurol. Neurosurg. Psychiatry 66, 636-640 (1999).
44. Nevalainen, O. et al. Long-term mortality risk by cause of death in newly diagnosed patients with epilepsy in Finland: a nationwide register-based study. Eur. J. Epidemiol. 28, 981-990, doi: 10.1007/s10654-013-9848-1 (2013).
45. Gaitatzis, A., Carroll, K., Majeed, A. & Sander, J. W. The epidemiology of the comorbidity of epilepsy in the general population. Epilepsia 45, 1613-1622, doi: 10.1111/j.0013-9580.2004.17504.x (2004).
46. Singh, G., Fletcher, O., Bell, G. S., McLean, A. E. & Sander, J. W. Cancer mortality amongst people with epilepsy: a study of two cohorts with severe and presumed milder epilepsy. Epilepsy Res. 83, 190-197, doi: 10.1016/j.eplepsyres.2008.11.001 (2009).
47. Fairhurst, C., Watt, I., Martin, F., Bland, M. & Brackenbury, W. J. Exposure to sodium channel-inhibiting drugs and cancer survival: protocol for a cohort study using the QResearch primary care database. BMJ Open 4, e006604, doi: 10.1136/bmjopen-2014-006604 (2014).
48. Hippisley-Cox, J., Stables, D. & Pringle, M. QRESEARCH: a new general practice database for research. Inform. Prim. Care 12, 49-50 (2004).
49. Vinogradova, Y., Coupland, C. & Hippisley-Cox, J. Exposure to bisphosphonates and risk of gastrointestinal cancers: series of nested case-control studies with QResearch and CPRD data. BMJ 346, f114, doi: 10.1136/bmj.f114 (2013).
50. Reeves, D. et al. Can analyses of electronic patient records be independently and externally validated? The effect of statins on the mortality of patients with ischaemic heart disease: a cohort study with nested case-control analysis. BMJ Open 4, e004952, doi: 10.1136/bmjopen-2014-004952 (2014).
51. Chisholm, J. The Read clinical classification. BMJ: British Medical Journal 300, 1092-1092 (1990).
52. Nielsen, S. F., Nordestgaard, B. G. & Bojesen, S. E. Statin Use and Reduced Cancer-Related Mortality. New England Journal of Medicine 367, 1792-1802, doi: 10.1056/NEJMoa1201735 (2012).
53. Grambsch, P. M. & Therneau, T. M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81, 515-526 (1994).
54. Pocock, S. J., Clayton, T. C. & Altman, D. G. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet 359, 1686-1689, doi: 10.1016/s0140-6736(02)08594-x (2002).